Hong Seng's unit signs collaborative agreement with Mediven

Hong Seng executive director and HS Bio director Christopher Chan

KUALA LUMPUR: Hong Seng Consolidated Bhd’s healthcare arm HS Bio Sdn Bhd has signed a collaboration agreement with Mediven Innovation Ventures Sdn Bhd to expand their respective coverage in the healthcare sector.

Mediven is a group of companies involved in the healthcare sector and has approvals, licences accreditations

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Hong Seng , HS Bio , Mediven®

Next In Business News
FBM KLCI rebounds to reclaim 1,700 level
Oil prices fall as risks from Kazakh production halt subside
Gold zooms past US$4,800 for the first time as Greenland tensions simmer
Maybank aims to mobilise RM300bil in sustainable finance by 2030
Airbus reaffirms long-term commitment to Malaysia’s aerospace sector
High court approves Capital A's capital reduction, working towards PN17 status uplift
Stocks shaken by geopolitical fears, Japanese bonds bounce after selloff
China completes first phase of 6G technology trials
ACE Market-bound Kee Ming Group to raise RM31.50mil from IPO
Bursa Malaysia continues uptrend at midday, CI stays above 1,700

Trending in Business

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.